UNSPSC 51171962: Ursodeoxycholic acid or ursodiol

This classification denotes a protein kinase c inhibitor and anti-lipidemic agent with the molecular formula C24H40O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 724L30Y2QR, chemically known as cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.beta.)- but more generally known as ursodeoxycholic acid, which bears US NIH Compound Identifier 5645. European Medicines Agency schedules Ursodeoxycholic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11389MIG.

UNSPSC 51171962 Ursodeoxycholic acid or ursodiol is a Commodity code covering a specific pharmaceutical active ingredient used primarily in bile acid replacement and gallstone dissolution therapies. Recent state and local procurement activity shows minimal relevant solicitation under this code; the three opportunities posted since early 2026 address broader pharmaceutical sourcing, drug testing services, and cooperative purchasing frameworks rather than ursodiol as a discrete product line. The code appears to see limited standalone procurement at the state and local level, with demand more likely embedded within general pharmaceutical supply agreements or institutional formulary contracts rather than solicited as a named active pharmaceutical ingredient.

The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 seeking vendor capabilities for a Direct-to-Manufacturer Prescriptions program, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 on January 20, 2026 (response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon — both representing indirect pathways through which ursodiol might reach end-use institutions rather than direct procurement of the ingredient itself. Neither solicitation names ursodiol specifically. Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services (response due July 23, 2026) involves pharmaceutical testing methodologies rather than procurement of the active ingredient. Geographic activity concentrates in Texas and the upper Midwest, but no recent opportunities directly target ursodiol procurement at quantifiable volume or value, limiting near-term pursuit signals under this specific code.